The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
June 28, 2021
Casimersen (Amondys 45) for Duchenne Muscular Dystrophy (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Casimersen (Amondys 45) for Duchenne Muscular Dystrophy (online only)
June 28, 2021 (Issue: 1627)
Casimersen (Amondys 45 – Sarepta), an IV antisense
oligonucleotide, has received accelerated approval
from the FDA for treatment of Duchenne muscular
dystrophy (DMD) in patients who have mutations
of the dystrophin gene that are amenable to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.